H1

The FDA released updated draft guidance in June that further defines requirements around race & ethnicity in #DiversityActionPlans. Clinical study #enrollment goals must be separated into these and other demographic characteristics of the clinically relevant population. With H1, sponsors now have access to granular, patient-level #diversitydata to meet new requirements effortlessly, leading to a significant reduction in trial site selection. Learn more about our diversity solutions here: https://hubs.la/Q02H5bHl0 See the FDA's draft guidance here: https://hubs.la/Q02H59KH0... #diversityactionplans #clinicaltrialdiversity #healthequity #fdadraftguidance #diversitydata

Year after year, the pressure on #medicalaffairs to help expedite the delivery of new treatments to market continues to grow. But for medical affairs teams to be able to refine their strategies, they need a way to analyze the impact of their activities. In this presentation, Christine Medeiros, H1’s Sr. Director of Strategic Insights, shares some real world examples of how data insights can help field teams identify value and find new paths to success. Watch it here: https://lnkd.in/eU6Ed6iU #measuringimpact #scientificshareofvoice #hcpsentiment #patientoutcomes #healthcaredata

Check out this thought-provoking article by our Regional VP of Sales, Trial Landscape, Ryan B., in MedCity News. As the clinical trial landscape evolves, inclusion, innovation, and scalability are key to developing treatments for diverse patient populations. 📌 Inclusion: Accessible trials representing diverse populations 📌 Innovation: Using AI and wearables to enhance processes 📌 Scalability: Global trials reflecting real-world scenarios Brown emphasizes the strategic use of data and technology to ensure comprehensive and efficient trials. Read the full article here: https://hubs.la/Q02GWXlt0 #ClinicalTrials #Innovation #Inclusion #Scalability #Healthcare #healthtech #MedTech

There's still time to register for our monthly H1 Connect webinar taking place in 2 days! This month, we're joined by Andrea Leiner, Deputy Director of Global Response Medicine, and Dr. Adam Ackerman. Global Response Medicine is an NGO delivering emergency care when there is war, conflict, or disaster, and the most vulnerable populations are caught in the crossfire. Dr. Ackerman recently deployed to Ukraine with Global Response Medicine. During this conversation, we'll learn more about Global Response Medicine, and hear directly from Dr. Ackerman about his recent deployment. Register here: https://hubs.la/Q02F_-Dg0

Thermo Fisher Scientific is partnering with the National Cancer Institute (NCI) to research new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). In the myeloMATCH umbrella trial, Thermo Fisher is testing patients for certain genetic biomarkers to more quickly match them with the right clinical trials to test treatments that target their specific mutations. myeloMATCH consists of a portfolio of sub-studies designed to treat patients with specific subtypes of AML and MDS. How incredible! https://hubs.ly/Q02GfD6v0

In order to reach larger and more diverse patient populations, clinical trial teams need to be able to scale globally. But doing so comes with numerous challenges, including the ability to recruit and retain patients for studies. H1’s data insights can help identify optimal trial sites and more inclusive patient pools to support expedited enrollment and more successful trials that ensure patient safety. Learn more: https://lnkd.in/gc2PcwmB #patientenrollment #clinicaltrialdiversity #healthequity

Data is a powerful tool at the fingertips of Medical Affairs, and its power comes in the meaningful stories it allows medical teams to tell. But finding those stories requires knowing what data to measure and having the right tools to do so. In order to more accurately measure Medical Affairs influence, we’ve identified 4 key categories of metrics that can be calculated to effectively demonstrate the level of impact. Learn more by downloading the industry report: https://lnkd.in/ebTa6448

This month, we're joined by Andrea Leiner, Deputy Director of Global Response Medicine, and Dr. Adam Ackerman. Global Response Medicine is an NGO delivering emergency care when there is war, conflict, or disaster, and the most vulnerable populations are caught in the crossfire. Dr. Ackerman recently deployed to Ukraine with Global Response Medicine. During this conversation, we'll learn more about Global Response Medicine, and hear directly from Dr. Ackerman about his recent deployment. Register here: https://hubs.la/Q02FWf6M0

In the joint effort to improve representation in clinical trials, CROs play a vital role. The future of #healthequity is the shared responsibility of both sponsors and CROs, and there are many challenges to overcome. In a recent interview with Daniel Perez, Global Head of Health Equity Strategy for Worldwide Clinical Trials, he called out the stigma still associated with mental health, for example. Black Americans are a commonly underserved group that disproportionately ends up in emergency rooms and are simply assigned an ICD-10 code regarding mental health conditions. There are many factors like this that can impact the pre-screening that CROs conduct, and Perez shared examples of how to improve it. Learn more by reading the blog post: https://hubs.la/Q02Fgl_y0

Eli Lilly and Company continues to expand on their “Get Better” campaign that pinpoints and addresses various health inequities they’ve identified. In this next stage of their campaign, Lilly is now highlighting issues related to the diagnosis and treatment of people of color with skin conditions. Lilly calls out the fact that dermatological diseases appear differently on different skin tones. Many HCPs do not have the necessary education to adequately diagnose patients of color and Lilly wants to help. Incredible steps toward improving #healthequity! https://hubs.la/Q02F0yNR0